NovoCure Ltd (NASDAQ: NVCR) on Monday, soared 3.89% from the previous trading day, before settling in for the closing price of $11.32. Within the past 52 weeks, NVCR’s price has moved between $10.91 and $34.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -83.87%. The company achieved an average annual earnings per share of -1.22%. With a float of $99.04 million, this company’s outstanding shares have now reached $111.80 million.
Let’s determine the extent of company efficiency that accounts for 1488 employees. In terms of profitability, gross margin is 76.38%, operating margin of -27.42%, and the pretax margin is -22.54%.
NovoCure Ltd (NVCR) Insider Activity
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of NovoCure Ltd is 11.41%, while institutional ownership is 76.86%. The most recent insider transaction that took place on Jul 29 ’25, was worth 231,800. In this transaction Chief Financial Officer of this company bought 20,000 shares at a rate of $11.59, taking the stock ownership to the 141,150 shares. Before that another transaction happened on Jun 03 ’25, when Company’s Director sold 999 for $17.28, making the entire transaction worth $17,259. This insider now owns 3,054 shares in total.
NovoCure Ltd (NVCR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -1.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.18% during the next five years compared to -83.87% drop over the previous five years of trading.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
NovoCure Ltd (NVCR) is currently performing well based on its current performance indicators. A quick ratio of 1.39 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.56, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.68 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Looking closely at NovoCure Ltd (NASDAQ: NVCR), its last 5-days average volume was 2.75 million, which is a jump from its year-to-date volume of 1.18 million. As of the previous 9 days, the stock’s Stochastic %D was 11.05%.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 7.99%, which indicates a significant decrease from 13.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.92 in the past 14 days, which was higher than the 0.88 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.53, while its 200-day Moving Average is $20.07.
